Clinical Trials Browser

NCT04039230 2026-03-16

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

75 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03990896 2025-08-07

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03964532 2025-05-21

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT04892693 2025-04-17

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Phase 2 Recruiting

70 enrolled

Breast

Advanced Breast Cancer

NCT06193525 2025-02-28

FUTURE

Phase 2 Recruiting

66 enrolled

Breast

Breast Neoplasms

NCT04703920 2025-01-23

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Phase 1 Completed

26 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04819243 2025-01-03

Young-PALETTA

Phase 2 Recruiting

178 enrolled

Breast

Premenopausal HR+/HER2- Metastatic Breast Cancer

NCT03911973 2024-06-07

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Phase 1/2 Active not recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1 Completed

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04690855 2023-12-04

TARA

Phase 2 Terminated

1 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03426254 2023-03-29

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT02401347 2023-02-21

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Phase 2 Completed

21 enrolled 12 charts

Breast

Triple Negative Breast Neoplasms

NCT02282345 2022-07-06

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Phase 2 Completed

36 enrolled 14 charts

Breast

Breast Adenocarcinoma

NCT05288127 2022-03-21

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Phase 2 Unknown

55 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04755868 2021-02-16

Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

Phase 2 Unknown

206 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02358200 2020-01-10

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Phase 1 Terminated

23 enrolled

BreastOther solid neoplasm

Triple Negative Metastatic Breast Cancer